Clinical outcome and cyclo‐oxygenase‐2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib

Albanese, Francesco; Abramo, Francesca; Caporali, Chiara; Vichi, Gaia; Millanta, Francesca

doi:10.1111/vde.12082

Cited by 9 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one study, 87.5% (7/8) of dogs with cutaneous SCC were found to have positivity for cyclo‐oxygenase‐2 (COX‐2) expression and 100% (9/9) in another study . Additionally, COX‐2 expression has also been identified in canine cases of actinic keratosis, and therapy with NSAIDs provided improvement in 4/5 dogs . NSAIDs have also been used in people with actinic keratosis with some efficacy as a topical therapy .…”

Section: Discussionmentioning

confidence: 99%

“…56,57 Additionally, COX-2 expression has also been identified in canine cases of actinic keratosis, and therapy with NSAIDs provided improvement in 4/5 dogs. 32,56,57 NSAIDs have also been used in people with actinic keratosis with some efficacy as a topical therapy. 58 Although it is difficult to draw conclusions from NSAID usage in this study, there is the impetus for future studies investigating the role of NSAIDs as chemoprevention for solar UV-radiation associated SCC in dogs.…”

Section: Discussionmentioning

confidence: 99%

“…A gold standard treatment approach has not been established for canine dermal SCC, however, some methods have been extrapolated from SCC in other locations and species. Reported treatment options for SCC have mainly centred on surgery, but there are also limited reports of photodynamic therapy, and medical therapies such as non‐steroidal anti‐inflammatories, retinoids and chemotherapy . Radiation therapy has been utilized for SCC arising in other locations, but has not been well described for dermal SCC in the dog…”

Section: Introductionmentioning

confidence: 99%

“…Reported treatment options for SCC have mainly centred on surgery, but there are also limited reports of photodynamic therapy, and medical therapies such as nonsteroidal anti-inflammatories, retinoids and chemotherapy. [29][30][31][32][33][34][35][36][37][38][39] Radiation therapy has been utilized for SCC arising in other locations, but has not been well described for dermal SCC in the dog. 40 Despite its relatively common occurrence, little has been published on the clinical features, behaviour or outcome of dogs with dermal SCC.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Clinical features and outcome of dermal squamous cell carcinoma in 193 dogs (1987‐2017)

Willcox

Marks

Ueda

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) is a frequently recognized dermal tumour in dogs and has been described as a common pathology induced by solar ultraviolet radiation exposure. Little has been published about this neoplasm with regard to clinical features and outcome in dogs. This retrospective study included 193 dogs from a single institution histopathologically diagnosed with SCC of the dermis. Thirty‐eight percent of all dogs had documented histopathologic actinic change. The overall median survival time was 1004 days, with the population demonstrating actinic change associated with a significantly longer survival time (median 1359 days, range 16‐3530 days) compared to dogs without actinic change (median 680 days, range 16‐3066 days) and this achieved significance on multivariate analysis (hazard ratio 0.42, 95% confidence interval 0.193‐0.930, P = 0.032). These data demonstrate increased survival of dogs with SCC demonstrating actinic change over those with non‐actinic SCCs, and purports long‐term survival for these animals. Dogs received a variety of treatment approaches as a retrospective study, and future prospective studies will be necessary to investigate whether adjunct therapies such as radiation or chemotherapy offer improvement in survival for dermal SCC in the dog.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical features and outcome of dermal squamous cell carcinoma in 193 dogs (1987‐2017)

Willcox

Marks

Ueda

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…In veterinary medicine, firocoxib is largely used for the management of osteoarthritis or surgical pain . Recently, it has been successfully tested in dogs with solar dermatitis and hyperplastic/dysplastic epithelial lesions of potential preneoplastic significance . Furthermore, a study demonstrated the antitumor activity of firocoxib as single agent or in association with cisplatin in dogs with transitional cell carcinoma …”

Section: Introductionmentioning

confidence: 99%

Combination of Radiation Therapy and Firocoxib for the Treatment of Canine Nasal Carcinoma

Cancedda

Sabattini

Bettini

et al. 2015

Vet Radiology Ultrasound

View full text Add to dashboard Cite

Carcinomas represent two-thirds of canine nasosinal neoplasms. Although radiation therapy (RT) is the standard of care, the incidence of local recurrence following treatment is high. Cyclooxygenase-isoform-2 (COX-2) is expressed in 71-95% of canine nasal carcinomas and has been implicated in tumor growth and angiogenesis. Accordingly, COX-2 inhibition seems rational to improve outcome. Dogs with histologically confirmed, previously untreated nasal carcinomas were randomized to receive the combination of a selective COX-2 inhibitor (firocoxib) and palliative RT (Group 1) or RT and placebo (Group 2). Patients were regularly monitored with blood tests, urinalysis, and computed tomography. Pet owners were asked to complete monthly a quality-of-life questionnaire. Twenty-four dogs were prospectively enrolled. According to Adams modified system, there were five stage 1, five stage 2, three stage 3, and 11 stage 4 tumors. Two dogs had metastases to regional lymph nodes. Median progression-free interval and overall survival were 228 and 335 days in Group 1 (n = 12) and 234 and 244 days in Group 2 (n = 12). These differences were not statistically significant. The involvement of regional lymph nodes was significantly associated with progression-free interval and overall survival (P = 0.004). Quality of life was significantly improved in Group 1 (P = 0.008). In particular, a significant difference was observed for activity and appetite. Although not providing a significant enhancement of progression-free interval and overall survival, firocoxib in combination with RT is safe and improved life quality in dogs with nasal carcinomas.

show abstract

Environmental skin disorders

Coyner¹

2019

Clinical Atlas of Canine and Feline Dermatology

View full text Add to dashboard Cite

Clinical outcome and cyclo‐oxygenase‐2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib

Abstract: A role for COX-2 might thus be hypothesized in the pathogenesis of canine solar dermatitis.

Cited by 9 publications

References 20 publications

Clinical features and outcome of dermal squamous cell carcinoma in 193 dogs (1987‐2017)

Clinical features and outcome of dermal squamous cell carcinoma in 193 dogs (1987‐2017)

Combination of Radiation Therapy and Firocoxib for the Treatment of Canine Nasal Carcinoma

Environmental skin disorders

Contact Info

Product

Resources

About